Flecainide versus propafenone for atrial fibrillation rhythm control

Atrial fibrillation affects more than 460,000 Australians and remains one of the most common reasons for cardiac hospitalisation across Sydney, Melbourne, and Perth. Within a rhythm-control strategy, Class IC antiarrhythmic agents are frequently selected for patients without significant structural heart disease, and two oral options dominate clinical practice.

Both are listed on the Pharmaceutical Benefits Scheme and are widely available through community pharmacies, yet head-to-head comparisons remain surprisingly sparse. Flecainide acetate and propafenone hydrochloride share many electrophysiological properties, but their subtle pharmacological differences shape patient selection. Australian electrophysiologists often default to one or the other based on local familiarity, training background, and the presence of coexisting conditions such as hypertension, asthma, or mild coronary disease.

This makes a careful comparison clinically relevant rather than purely academic. For Australian prescribers, the choice is not just pharmacological. PBS criteria, out-of-pocket cost for non-subsidised indications, and the logistics of inpatient initiation versus outpatient loading all influence the decision. Understanding where the two agents diverge helps clinicians tailor therapy to the individual sitting in front of them rather than relying on inherited habits.

This overview synthesises contemporary evidence on efficacy and proarrhythmic risk, then frames the discussion around Australian realities including guideline recommendations from the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand.

Class IC pharmacology and mechanistic similarities

Both agents block the rapid inward sodium current responsible for phase 0 depolarisation in atrial and ventricular myocytes. They exhibit strong use-dependence, meaning their effect intensifies at faster heart rates, which also explains their proarrhythmic potential under catecholamine surge. Both prolong the PR interval and widen the QRS on the surface electrocardiogram, and both are metabolised hepatically via the cytochrome P450 system, although through different isoforms.

The key divergence lies in additional channel activity. Propafenone carries intrinsic beta-adrenoceptor blocking properties, roughly equivalent to low-dose metoprolol at standard antiarrhythmic doses. This matters for patients with reactive airways disease, where flecainide is often preferred, and for patients with a tachycardic tendency at rest, where propafenone may blunt sinus rates more effectively. Conversely, the beta-blockade can aggravate bronchospasm in susceptible individuals, a point worth documenting in clinic letters shared with GPs in regional centres such as Bendigo or Launceston.

Flecainide's half-life of approximately 14 hours supports twice-daily dosing, while propafenone's shorter elimination in extensive metabolisers often requires three times daily administration. In poor metabolisers, who represent roughly 7 percent of the Australian population, propafenone levels accumulate and QRS widening becomes more pronounced, necessitating dose reduction or alternative therapy.

Comparative efficacy for acute and long-term rhythm control

Direct head-to-head trials of flecainide and propafenone are limited, but the pooled indirect evidence suggests broadly comparable efficacy for cardioversion of recent-onset atrial fibrillation. Conversion rates within eight hours of oral loading cluster around 70 to 80 percent for both agents when the arrhythmia is under seven days in duration, and both outperform placebo. Differences in time-to-conversion have not consistently favoured one drug over the other across European and South American cohorts.

For long-term maintenance of sinus rhythm, meta-analyses of Class IC agents versus placebo show approximately a 40 to 50 percent relative reduction in AF recurrence over twelve months. Few studies directly randomise between the two drugs, and the largest comparative dataset comes from registry analyses in Italy and Germany, which suggest similar hazard ratios for recurrence. Patient factors such as left atrial size, body mass index, and burden of atrial premature complexes appear to influence outcomes more than the choice between flecainide and propafenone.

In Australian practice, this means that switching from one agent to the other after apparent failure is rarely justified unless a specific adverse effect is identified. Reassessment of triggers, alcohol intake during summer festivities in Adelaide, and sleep apnoea screening often yields more benefit than medication substitution.

Proarrhythmic risk profiles and safety signals

The shadow of the Cardiac Arrhythmia Suppression Trial still influences contemporary prescribing. While the CAST findings relate to post-myocardial infarction patients with ventricular ectopy, the lesson that Class IC agents can be proarrhythmic in diseased myocardium shapes the absolute contraindications for both flecainide and propafenone. Neither should be used in patients with prior myocardial infarction, significant coronary artery disease, or reduced left ventricular ejection fraction below 40 percent.

Beyond ventricular risk, both drugs can convert atrial fibrillation into slow atrial flutter with 1:1 conduction, producing paradoxically rapid ventricular rates. This phenomenon is more frequent with flecainide monotherapy and can be mitigated by co-prescription of an atrioventricular nodal blocker. Propafenone's intrinsic beta-blockade offers partial protection against this complication, which is one of the subtle reasons it remains popular among clinicians managing patients with paroxysmal AF in Brisbane and the Sunshine Coast.

QRS widening beyond 25 percent of baseline warrants dose reduction or cessation, and PR prolongation above 200 milliseconds should prompt review. Serum levels are not routinely monitored, but electrolyte optimisation, particularly potassium and magnesium, is essential in the Australian summer when heat-related diuresis is common.

Patient selection in the Australian context

The Pharmaceutical Benefits Scheme subsidises both flecainide and propafenone for rhythm control in atrial fibrillation, but authority requirements specify documented absence of significant structural heart disease and failure or intolerance of at least one first-line alternative. This steers many patients through a beta-blocker or sotalol trial before Class IC therapy, although in practice the sequence varies between metropolitan electrophysiology clinics in Melbourne and tertiary centres in Perth.

Geography matters. Patients in remote Western Australia or far-north Queensland may have limited access to immediate cardioversion if proarrhythmia develops, which influences some rural physicians to prefer an AV node-ablating pace-and-ablate strategy instead of Class IC drugs. Telehealth reviews with a cardiologist based in Darwin or Adelaide can support safer initiation in selected cases, but thorough baseline evaluation including echocardiography remains non-negotiable. For patients with cardioverter-defibrillators who require surgical procedures, perioperative ICD management reviews current best practice on electrocautery and magnet response.

For patients considering the pill-in-the-pocket approach after successful inpatient cardioversion, both agents are suitable provided they are haemodynamically stable, have a normal resting ECG, and have demonstrated tolerability during supervised loading. Written action plans and clear thresholds for seeking emergency care at the nearest emergency department form part of standard counselling.

Dosing, monitoring, and drug interactions

Flecainide is typically started at 50 mg twice daily, titrated to 100 mg twice daily if tolerated and clinically indicated. Propafenone dosing usually begins at 150 mg three times daily, escalating to 300 mg three times daily in extensive metabolisers. Dose adjustments are necessary in renal impairment for flecainide and in hepatic dysfunction for propafenone, which is relevant for the management of patients with concomitant alcohol-related liver disease seen not uncommonly in tertiary hospital practice.

Drug interactions deserve attention. Flecainide levels rise with amiodarone co-administration, and the combination is generally avoided. Propafenone interacts with warfarin through CYP2C9 inhibition, often necessitating INR monitoring after initiation. Both agents can increase digoxin concentrations, and both potentiate the negative inotropic effect of beta-blockers, although propafenone's intrinsic beta-blockade makes this interaction more pronounced.

Outpatient initiation is feasible for selected patients without structural heart disease when facilities for telemetry monitoring and emergency resuscitation are available. For those in regional areas without immediate access to such resources, inpatient loading during a short hospital admission remains the safer pathway.

Special populations: athletes, the elderly, and heat exposure

Endurance athletes, including the growing community of marathon runners and cyclists along Sydney's coastal routes, present unique considerations. Flecainide's use-dependent block can be advantageous during high catecholamine states, but caution is warranted in those with underlying early repolarisation or concealed accessory pathways. Propafenone's beta-blockade may impair exercise performance in competitive athletes, making flecainide the preferred agent in many cases.

Elderly patients in aged-care facilities across Hobart and Canberra often have reduced renal function and multiple comorbidities. Lower starting doses, slower titration, and regular ECG checks are prudent. Cognitive concerns can affect adherence to three-times-daily propafenone, favouring twice-daily flecainide in this group.

Aboriginal and Torres Strait Islander peoples experience a higher burden of rheumatic heart disease and atrial fibrillation at younger ages. When structural involvement is present, Class IC agents should generally be avoided, and rate control with anticoagulation prioritised. Where rheumatic disease is mild and ventricular function preserved, shared decision-making with culturally safe care pathways supports individualised therapy.

Integrating the evidence into everyday practice

The choice between flecainide and propafenone ultimately rests on subtle patient-specific factors rather than dramatic differences in efficacy. Clinicians should weigh the presence of reactive airways disease, the need for intrinsic rate control, dosing convenience, and local access to monitoring. For most patients without structural heart disease, both are reasonable first-line Class IC options.

Australian guidelines from the National Heart Foundation emphasise shared decision-making, careful baseline assessment, and structured follow-up. Recording the indication, baseline ECG, and patient consent in the clinic letter supports continuity across primary and tertiary care. Local arrhythmia interest groups in Sydney and Melbourne regularly update members on emerging evidence, offering an accessible forum for case discussion.

Clinicians are invited to share their experience through case reports, brief communications, or systematic reviews that enrich the local evidence base. Detailed instructions for manuscript preparation and submission are available through the journal's author guidelines, and the editorial team welcomes contributions that reflect the realities of arrhythmia care across Australian practice settings. Readers managing complex presentations are encouraged to engage with the correspondence section, where challenging scenarios are discussed in an open and educational format.